MINISO Group Holding Ltd vs Smith & Nephew plc — how do they compare? MINISO Group Holding Ltd trades at $11.97 (market cap $3.62B), while Smith & Nephew plc trades at $29.95 (market cap $12.54B). The key difference: Smith & Nephew plc is far larger — about 3.5× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays the higher dividend (5.53%). Which is the better fit depends on your goals.
| MNSO | SNN | |
|---|---|---|
Market Cap | $3.62B | $12.54B |
Sector | Technology | Health |
52-Week High | $26.63 | $38.70 |
52-Week Low | $11.30 | $28.73 |
Enterprise Value | $4.29B | $15.57B |
Dividend Yield | 5.53% | 2.65% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Smith & Nephew (SNN) trades at $30.08, down 0.1% with bearish technical signals. The company reported mixed Q2 2026 results with revenue growth below expectations, leading to a reduced full-year outlook. Fundamentals show strong profitability with 10.1% net margin and improving cash flow trends, though recent earnings misses have tempered sentiment.
Outlook remains cautious with analyst consensus at Hold (65% of coverage). Near-term risks include U.S. orthopedics weakness and competitive pressures, offset by robotics innovation and value-based care expansion. The stock offers stable fundamentals but faces execution challenges in key markets.
Trailing returns across standard periods
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →